Trefoil Therapeutics Begins First Clinical Trial of Regenerative Treatment for Patients with Corneal Endothelial Dystrophies
One principle guides our investments: invest in companies that will improve patients' lives. We have found that the best founders and executive teams share that belief. From our first meeting to an email this week, the Trefoil Therapeutics team has consistently echoed that sentiment. Today they take a big step forward to meeting that goal by announcing that they have started the first clinical trial of their regenerative treatment for people with corneal endothelial dystrophies. Congratulations to them on this accomplishment!
Phase 1/2 “INTREPID” trial to evaluate safety and ability of engineered FGF-1 to regenerate corneal endothelial cells San Diego, CA – August 19, 2020 – Trefoil Therapeutics today announced it has initiated the first clinical trial of its engineered Fibroblast Growth Factor-1 TTHX1114 for the regenerative treatment of people with corneal endothelial dystrophies (CED), including Fuchs Endothelial Corneal Dystrophy. The Phase 1/2 trial (“INTREPID”) is designed to evaluate TTHX1114’s safety and ability to stimulate the regeneration of corneal endothelial cells lost due to CED when administered by intracameral (back of the cornea) injection. Continue reading
Watch CEO David Eveleth at OIS@AAO.